Introduction {#S1}
============

The field of T-cell costimulation started with the "two-signal" theory of lymphocyte activation that was originally proffered to distinguish self from non-self. This model explains the process of activation or anergy when a naive T cell confronts an antigen ([@B1], [@B2]). As per this model, two signals from antigen-presenting cells (APCs) are required for effective activation of a naive T cell. The first signal confers specificity to the immune response and involves antigen recognition, provided by the interaction of antigenic peptide/major histocompatibility complex (MHC) with the T cell receptor (TCR). The second antigen-independent signal is the "costimulatory signal," delivered by costimulatory molecules expressed on APCs to receptors expressed on T cells. If a T cell receives only antigen-specific TCR stimulation in the absence of costimulation, it will become unresponsive (anergic) to subsequent antigenic challenge ([@B3], [@B4]). Later, negative costimulatory (i.e., coinhibitory) signals were also found to exist. Receptors delivering coinhibitory signals function as immune checkpoints and play a decisive role in maintaining peripheral tolerance and impeding autoimmunity ([@B5]--[@B8]).

The best-studied pathway for T cell costimulation includes B7-1/B7-2--CD28/CTLA-4 superfamily, which is essential for T cell activation and tolerance ([@B9]--[@B13]). While both the receptors and ligands of this superfamily are structurally type I transmembrane protein with a single IgV extracellular domain that predominantly mediates the receptor--ligand interaction, the ligands also contain an IgC domain on their outer surface. The immune system functions by maintaining an intricate balance between CD28/costimulation-mediated T cell activation and CTLA-4/immune checkpoint-mediated inhibition. Identification of the programed cell death 1 (PD-1) as another inhibitory receptor and inclusion of its ligands as additional members of the B7-1/B7-2--CD28/CTLA-4 family ([@B14], [@B15]) re-established the importance of immune checkpoints to safeguard the maintenance of T cell tolerance. Since the beginning of its discovery, costimulation had been of therapeutic interest because it was thought to provide a way to promote T cell activation to enhance antitumor responses. But with the discovery of CTLA-4 as a potent inhibitory immune checkpoint, the notion about cancer immunotherapy was modified and the preferred approach was understood as not to activate the immune system to attack cancer but to remove the coinhibitory signals that block antitumor T cell responses. Based on the same concept, the PD-1/PD-L1 coinhibitory pathway was exploited therapeutically resulting in remarkable outcomes with 20--90% response rates in multiple clinical trials and various types of cancer ([@B16]--[@B19]).

Discovery of the PD-1:PD-L1 Pathway {#S2}
===================================

While studies have shown that PD-1--PD-L interaction is important to maintain a balance between peripheral tolerance and autoimmunity, it also impairs viral and tumor immunity, promoting chronic infection and tumor progression. PD-1 is a 288 amino acid protein mostly expressed on the surface of activated T cells ([@B20]--[@B23]). In 1992, PD-1 was identified as an apoptosis-associated molecule ([@B24]). In an attempt to identify gene(s) important for apoptosis, Tasuku Honjo and colleagues at Kyoto University performed subtractive-hybridization assay and PD-1 cDNA was found to be encoded by all of the isolated clones. However, its overexpression had no effect on apoptosis in the studied cell lines ([@B23]). In 1999, the same group demonstrated PD-1 to be a negative regulator of immune responses by studying PD-1-deficient mice, which developed an autoimmune phenotype with delayed onset, organ-specific effects and incomplete penetrance. While CTLA-4 deficiency caused the rapid-onset of systemic autoimmunity, PD-1 deficiency resulted in spontaneous development of lupus like arthritis, splenomegaly, glomerulonephritis, increased number of B-lymphocytes and myeloid cells, and increased serum IgA, IgG2b and IgG3 in C57BL/6 mice. Interestingly, PD-1 deletion in Balb/c background resulted in a distinct autoimmune phenotype as early as of 5 weeks of age, with dilated cardiomyopathy, gastritis, and high circulating level of troponin reactive IgG1. PD-1 deficiency induced subacute type I diabetes in non-obese diabetic (NOD) mice whereas lethal myocarditis was observed in mice with MRL background ([@B8], [@B25]--[@B27]). Introduction of the lpr mutation, which causes absence of Fas-mediated apoptosis pathway (B6-lpr/lpr-PD-1^−^/^−^), expedited the commencement and severity of the disease. However, no disease was developed in Balb/c-PD-1^−^/^−^ RAG^−^/^−^ mice, showing the importance of lymphocytes for disease development. To study the response to autoantigens, PD-1-deficient 2C TCR transgenic mice were bred to the autoreactive background (H−2^b/d^) and the offspring displayed splenomegaly, growth retardation, and lethal graft versus host disease (GVHD) ([@B7]). The group collaborated with Genetics Institute at Cambridge, MA, USA, in an attempt to identify the ligand of PD-1.

Almost in parallel, Lieping Chen's group, then at Mayo Clinic, identified PD-L1, which was named B7-H1, as a molecule with homology to B7-1 and B7-2 ([@B28]). The group did not discover that B7-H1 is a ligand for PD-1 but reported that B7-H1 costimulates T cells *via* a receptor different from CD28, CTLA4, or ICOS and delivers an activation signal to T cells, which leads to IL-10 production, but not to detectable levels of IL-2. A third, independent research group led by Gordon Freeman at Dana--Farber Cancer Institute identified by database search a B7-like molecule that did not interact with CD28, CTLA4 or ICOS. The group collaborated with Genetics Institute at Cambridge, MA, USA, in order to identify its receptor. Through these interactions with the two independent groups, the researchers at Genetics Institute found that this B7-1 like molecule was a ligand for PD-1, and was then named PD-L1 (*Pdcd1lg1*, CD274) for PD-1 ligand 1 ([@B14]). The collaboration further identified the second PD-1 ligand, named PD-L2 (*Pdcd1lg2*, CD273) ([@B15]).

Molecular Structure {#S3}
===================

Programed cell death 1 is composed of a single N-terminal IgV-like domain sharing 21--33% sequence identity with CTLA-4, CD28, and ICOS, about 20-amino acid stalk separating the IgV domain from the plasma membrane, a transmembrane domain, and a cytoplasmic tail containing two tyrosine-based signaling motifs. Since PD-1 lacks the membrane proximal cysteine residue, which is essential for homodimerization, it is believed to exist as monomer on the cell surface ([@B29]). Unlike CD28 and CTLA-4, PD-1 tail does not contain any SH2- or SH3-binding motifs. Instead, it contains an N-terminal sequence VDYGEL, forming an immunoreceptor tyrosine-based inhibitory motif (ITIM), which is required for recruiting SH2 domain-containing phosphatases ([@B30]) and a C-terminal sequence TEYATI, forming an immunoreceptor tyrosine-based switch motif (ITSM), essential for the inhibitory function of PD-1 ([@B31], [@B32]). The ligands of PD-1 (PD-L1 and PD-L2) are type I transmembrane glycoproteins, containing IgC and IgV domains. The amino acid identity between PD-L1 and PD-L2 is about 40%, while PD-Ls and B7s have about 20% similarity. Human and murine orthologs of PD-Ls display about 70% identity. The crystal structure analysis shows that PD-1 utilizes its front β-face (AGFCC' β-strands) to bind to the β-face of PD-L1 (AGFCC' β-face) or PD-L2 (AGFC) ([@B29], [@B33], [@B34]).

Expression and Distribution of PD-1 and Its Ligands {#S4}
===================================================

Programed cell death 1 is expressed on activated CD4 and CD8 T cells, B cells, monocytes, natural killer (NK) cells, and dendritic cells (DCs) ([@B23], [@B35], [@B36]). PD-1 expression can also be induced on APCs, myeloid CD11c^+^ DCs, and monocytes ([@B37], [@B38]). The common γ chain cytokines interleukin-2 (IL-2), IL-7, IL-15, and IL-21 can induce PD-1 expression on T cells ([@B21]). PD-1 is expressed on CD4^−^CD8^−^ double-negative (DN) thymocytes and is essential for their selection during TCRβ rearrangement ([@B25], [@B39]). NFATc1 is an important transcription factor that promotes the induction of PD-1 expression following activation of T cells ([@B40]). PD-1 expression is significantly reduced by calcineurin inhibitor cyclosporine A and the NFAT-specific inhibitor VIVIT. Also mutation of an NFATc1 consensus-binding site causes complete loss of PD-1 expression in T cells. The other established transcriptional activators of PD-1 are Foxo1, Notch, and IRF9, while T-bet functions as a transcriptional repressor ([@B20], [@B41]--[@B43]). In macrophages, interferon (IFN)-sensitive responsive element (ISRE) and STAT1/2 regulate the constitutive and IFN-α-mediated PD-1 expression ([@B44]). PD-1 can also be selectively induced on myeloid DCs by *Listeria monocytogenes* infection or by Toll-like receptor 2 (TLR2), TLR3, TLR4, or NOD ligation, but is inhibited by IL-4 and TLR9 ([@B45]). PD-1 expression is also upregulated and sustained on "exhausted" virus-specific T cells during chronic viral infection preventing their proliferation and function in clearing the virus ([@B46], [@B47]).

PD-Ls have distinct expression patterns: PD-L1 is constitutively expressed on T and B cells, DCs, macrophages, mesenchymal stem cells and bone marrow-derived mast cells ([@B35]). In addition, PD-L1 is expressed on a wide variety of non-hematopoietic cells including lung, vascular endothelium, fibroblastic reticular cells, liver non-parenchymal cells, mesenchymal stem cells, pancreatic islets, astrocytes, neurons, and keratinocytes ([@B36]). It has also been shown to be expressed on placental syncytiotrophoblasts and functions in the placenta to induce fetal--maternal tolerance ([@B48], [@B49]). PD-L1 is expressed constitutively in the cornea and retinal pigmented epithelium (RPE) and PD-1--PD-L1 interaction protects the eye from activated T cells ([@B50]--[@B53]). In contrast, PD-L2 expression is restricted to activated DCs, macrophages, bone marrow derived mast cells, and more than 50% of peritoneal B1 cells ([@B54]). In the thymus, PD-L1 is expressed mostly in the cortex, while PD-L2 expression is confined in medullary stromal cells ([@B55], [@B56]). PD-L1 expression on human T cells are induced by common γ chain cytokines IL-2, IL-7, and IL-15, whereas IL-21 can stimulate PD-L1 expression on B (CD19^+^) cells from peripheral blood mononuclear cells (PBMCs). LPS or BCR activation also result in induction of PD-L1 and PD-L2 in human B cells ([@B14], [@B15], [@B28]). IFN-γ, but not tumor necrosis factor (TNF)-α, treatment results in the expression of both ligands in human monocytes. IL-10 can also induce the expression of PD-L1 on monocytes, while IL-4 and granulocyte macrophage colony-stimulating factor (GM-CSF) stimulate PD-L2 expression on DCs ([@B57]). IFN-γ can also regulate PD-L1 expression in non-lymphoid cells. Endothelial cells constitutively express PD-L1 on their surface and *in vitro* treatment with IFN-γ causes its rapid upregulation ([@B58]). In addition, MyD88, TRAF6, MEK, and JAK2 are also known to play important role in signaling pathways involved in PD-L1 expression ([@B59]--[@B61]). PD-Ls are also expressed on various tumor cells. PD-Ls mediate potent inhibitory signals after ligation with PD-1, causing a detrimental effect on antitumor immunity by allowing the tumor cells to escape immunosurveillance ([@B62]--[@B64]).

Effects of PD-1 on Signaling Pathways {#S5}
=====================================

Identification of PD-Ls and confirmation of their interaction with PD-1 established PD-1 as a negative regulator of immune responses ([@B14], [@B15]). Unlike other members of CD28 family, PD-1 transduces signal only when cross-linked together with B- or T-cell antigen receptor. PD-1-mediated signaling inhibits T lymphocyte glucose consumption, cytokine production, proliferation, and survival. CD28 costimulation ([@B14]) or IL-2 ([@B65]) can override PD-1-mediated inhibition. PD-1 engagement prevents the expression of transcription factors associated with effector cell function, including GATA-3, T-bet, and Eomes ([@B66]). Upon TCR stimulation, the tyrosine residues in the ITIM and ITSM motifs on the cytoplasmic tail of PD-1 become phosphorylated, recruiting SHP-1 and SHP-2, which in turn, dephosphorylate proximal signaling molecules downstream of the TCR and CD28. Positional mutagenesis studies have shown that the ITSM motif is critical for the inhibitory function of PD-1 ([@B22], [@B67]). Specifically the ITSM tyrosine (Y248) of PD-1 associates with SHP-2 and is mandatory for PD-1-mediated inhibition of PI3K/Akt activation ([@B22], [@B68]). PD-1 ligation causes diminished phosphorylation of CD3, ZAP70, and protein kinase Cθ ([@B69]). It can also inhibit Erk activation, which can be overcome through IL-2, IL-7, and IL-15 signaling ([@B70]). In B cells, PD-1 engagement inhibited B cell receptor-mediated Ca^2+^ mobilization and phosphorylation of Igβ, Syk, PLC-γ2, and Erk1/2, and these effects were dependent on SHP-2 recruitment to the ITSM tyrosine of PD-1 ([@B67]).

A puzzling question has been surfaced about the role of SHP-2 versus SHP-1 in the inhibitory function of PD-1. Recruitment of SHP-2 to the cytoplasmic tail of PD-1 has been well documented in B cell line ([@B67]), Jurkat T cells ([@B15]), and primary human T cells ([@B22], [@B71]). SHP-1 may also be a potential candidate for interaction with PD-1 cytoplasmic tail, as found by yeast two-hybrid screening. SHP-1 functions as a negative regulator of cell activation and its expression is largely confined to hematopoietic cells ([@B72]). SHP-1-deficient mice display prolonged phosphorylation of the TCR/CD3 complex and increased activation of Lck, Fyn, and other proximal TCR signaling components ([@B73]--[@B75]). In contrast, the role of SHP-2 in T cells is different. SHP-2 is omnipresent and SHP-2 deficiency results in embryonic lethality in mice. SHP-2 mostly has been depicted as a positive regulator of cell activation and appears to be necessary for optimal induction of MAPK/Erk pathway ([@B76]). SHP-2 can recruit insulin receptor substrate to insulin receptor ([@B77]) and Grb2 to both platelet-derived growth factor receptor ([@B78]) and erythropoietin receptor ([@B79], [@B80]). A live cell imaging study determined that SHP-2, but not SHP-1, is the phosphatase that interacts with PD-1 upon TCR-mediated activation in live cells ([@B81]). This work showed that PD-1 is translocated to dynamic TCR microclusters and accumulates at the signaling central supramolecular activation cluster (c-SMAC). SHP-2 is shortly recruited to PD-1 thereafter in the microclusters and associates with ITSM of PD-1 ([@B81]). Using site-directed mutagenesis and stable expression of mutagenized PD-1 constructs in Jurkat T cells, it was determined that although only mutation of PD-1 Y248 abrogated interaction with SHP-2, both Y248 and Y223 are actively involved in the inhibitory effects of PD-1 on IL-2 production ([@B82]).

Effects of PD-1 on TCR Signaling and Functional Outcomes {#S6}
========================================================

Programed cell death 1 ligation attenuates TCR-mediated signaling at a proximal level and impairs the activity of two signaling cascades, the PI3K/Akt and the Ras/MEK/Erk pathway ([@B68], [@B83]), which are co-required to initiate T cell activation (Figure [1](#F1){ref-type="fig"}). One of the many mechanisms *via* which PD-1 inhibits activation of the PI3K/Akt pathway includes PTEN phosphorylation and phosphatase activity, which is regulated by CK2 ([@B84]). CK2 mediates phosphorylation of PTEN C-terminus serine/threonine cluster S380/T382/T383, which, aids PTEN protein stability, while reducing PTEN lipid phosphatase activity against the substrate PIP3 ([@B85], [@B86]). During TCR/CD3- and CD28-mediated stimulation, PTEN is phosphorylated by CK2 ([@B84]), which stabilizes PTEN and suppresses its phosphatase activity. In contrast, PD-1 inhibits the stabilizing phosphorylation of the Ser/Thr cluster within the C-terminus domain of PTEN, resulting in increased PTEN phosphatase activity. The other major signaling pathway targeted by PD-1 is the Ras/MEK/Erk pathway ([@B69], [@B83]). The activation of Ras and its downstream MEK/Erk MAP kinase pathway in T cells comprises of the Ca^2+^ and DAG-mediated activation of RasGRP1 ([@B87]--[@B89]) downstream of PLC-γ1 ([@B90]), which is inhibited by PD-1 ([@B83]). Other signaling events initiated by TCR ligation are also attenuated by PD-1 ligation including activation of ZAP70 and PKCθ ([@B69]).

![**Effect of PD-1 on major signaling pathways and subsequent metabolic reprograming in T cells**. When T cell encounters a foreign antigen presented by MHC on the surface of APC, TCR gets phosphorylated upon oligomerization of TCR/CD3 chains, followed by recruitment of activated Lck and Zap-70 to the phosphorylated ITAM (tyrosine motifs) of TCR tail, leading to initiation of downstream TCR-signaling cascade. During TCR cross-linking, when PD-1 interacts with its ligands, the two tyrosine residues on PD-1 cytoplasmic tail also become phosphorylated, and SHP-2 is recruited to ITSM (also possibly SHP-1). As a consequence, Lck and Zap-70 become dephosphorylated. PD-1 ligation also causes inhibition of PI3K/Akt/mTOR and Ras/MAPK/Erk pathways, leading to downregulation of glycolysis and amino acid metabolism and increase in fatty acid oxidation in T cells. This alteration in T cell metabolic reprograming may change the course of T cell differentiation, leading to impaired differentiation of effector and memory T cells, while enhancing the differentiation of T regulatory cells and exhausted T cells.](fimmu-07-00550-g001){#F1}

PD-1 Targets the Cell Cycle {#S6-1}
---------------------------

A major downstream target of the synergistic effect of PI3K/Akt and Ras/MEK/Erk activation in T cells is the cell cycle machinery. Primary T lymphocytes naturally reside in the G0 phase and lack expression of cyclins, which are required to interact with cyclin-dependent kinases (Cdks) to form cyclin--Cdk holoenzyme complexes that drive cell cycle progression ([@B91]--[@B93]). p27^kip1^, a member of the Kip/Cip family of Cdk inhibitors, interacts with Cdk2 and is abundantly present in T cells. Ubiquitin-dependent degradation of p27^kip1^ is required to initiate cell cycle progression and entry to S phase by allowing activation of Cdk2. This event is predominantly mediated by Skp1-Cullin-F-box (SCF) family ubiquitin ligase, SCF^skp2^ ([@B94]). TCR/CD3 and CD28 costimulation regulates the transcriptional induction of Skp2, a substrateSCF^skp2^ ubiquitin ligase, and this process requires simultaneous activation of PI3K/Akt and Ras/MEK/Erk pathways ([@B95]). Ligation of PD-1 during the T cell stimulation causes abrogated expression of Skp2, resulting in increased p27^kip1^ level and Cdk2 inhibition ([@B83]). The impaired Cdk2 activity inhibits Rb phosphorylation, impacting its interaction with chromatin remodeling proteins. Inhibited Cdk2 also fails to phosphorylate the checkpoint inhibitor Smad3, upregulating its transcriptional activity ([@B96]) and resulting in the increased abundance of the G1 phase Cdk inhibitor, p15^INK4B^, and the loss of the Cdk-activating phosphatase Cdc25A ([@B83], [@B97]).

PD-1 Reduces the Threshold of TGF-β-Mediated Signaling {#S6-2}
------------------------------------------------------

One major consequence of PD-1-mediated Cdk2 inhibition and subsequent reprograming of Smad3 transcriptional events is the conversion of naive T cells into induced T regulatory cells. Regulatory T cell populations are critical for the maintenance of peripheral tolerance, are potent inhibitors of immune responses and play an important role in the prevention of graft rejection ([@B98], [@B99]). Foxp3^+^ T~Regs~ can be divided into two subsets: natural T~Regs~ (nT~Regs~) and induced T~Regs~ (iT~Regs~). CD4+Foxp3+nT~Regs~ arise as committed regulatory cells from thymus ([@B100]), while iT~Regs~ (or adaptive T~Regs~) develop in the periphery from CD4^+^Foxp3^−^ naive T cells in a TGF-β- and IL-2-dependent fashion ([@B101]--[@B107]). PD-1 regulates the function of Smad3 and synergizes with TGF-β-mediated signals ([@B83]). This synergizing effect on naive T cells promotes the differentiation of T~Reg~ cells ([@B108]), thereby suppressing generation and function of T effector cells (T~EFF~) *via* a cell extrinsic mechanism. In addition, generation and function of T~Reg~ cells requires the aLb2 (LFA-1) integrin, whose activity is dependent on small GTPase Rap1 ([@B109]--[@B112]). Importantly, PD-1 does not inhibit Rap1 activation ([@B83]), indicating that PD-1 also supports the pathways required for T~Regs~ to perform their immunosuppressive functions. Experiments with PD-L1-deficient APCs resulted in minimal conversion of naive CD4^+^ T cells to iT~Regs~. PD-L1-Ig has also been shown to increase Foxp3 expression and suppressive function of established iT~Regs~ through attenuation of Akt-mTOR signaling and concomitant upregulation of PTEN signaling events that are known to drive generation of iT~Regs~ ([@B108], [@B113]--[@B115]).

PD-1 Alters the Metabolic Program of Activated T Cells {#S6-3}
------------------------------------------------------

Upon activation, signals from the CD28 costimulatory pathway and the γ-chain signaling cytokines promote naïve T cells to switch their metabolism from oxidative phosphorylation to glycolysis, which is required to support their growth, proliferation, and effector functions ([@B116]--[@B119]). Divergence in the metabolic reprograming is critical for imprinting distinct T cell fates. Namely, preferential switching to glycolysis accompanies effector T cell differentiation ([@B120]) and switching to fatty acid beta-oxidation (FAO) causes the conversion of T effector to T memory cells ([@B121]). Furthermore, imposing FAO by pharmacologic means boosts the generation of T~Reg~ cells ([@B122]). Studies investigating metabolism profile of T cells receiving PD-1 signals have shown that PD-1 ligation disengaged them from glycolysis, glutaminolysis, or metabolism of branched chain amino acids, but induced increased rate of FAO ([@B123]). While PD-1 ligation inhibited the expression of receptors and enzymes involved in glycolysis and glutaminolysis, it increased the expression of carnitine palmitoyl transferase (CPT1A), the rate-limiting enzyme of FAO. T cell activation causes an increase in extracellular acidification rate (ECAR), an indicator of glycolysis, and in oxygen consumption rate (OCR), an indicator of oxidative phosphorylation. PD-1 engagement results in lower ECAR and OCR, but higher OCR/ECAR ratio compared with T cells stimulated without PD-1 ligation (Figure [1](#F1){ref-type="fig"}). By altering the metabolic programs of T cells, PD-1 ligation seems to generate a more oxidative environment ([@B123], [@B124]).

Clinical Implications of PD-1 Ligation on T Cell Immune Function {#S7}
================================================================

Role of PD-1 in Chronic Viral Infection: T Cell Exhaustion {#S7-1}
----------------------------------------------------------

Programed cell death 1 has unique regulatory roles in the control of virus-specific immune responses, and these regulatory functions have been studied extensively during chronic viral infections. The CD8^+^ effector T cells behave differently in acute and chronic viral infections. During acute infection, naïve antigen-specific CD8^+^ T cells get activated, proliferate, and differentiate into effector CD8^+^ T cells and efficiently clear the virus. Most of these virus-specific effector CD8^+^ T cells then become apoptotic and a very small number (5--10%) of long-lived memory cell population arises, which is protective against secondary infection ([@B125]). However, during chronic viral infection, sustained antigenic stimulation engenders the loss of effector T cells and their failure to develop into memory CD8^+^ T cells (Figure [2](#F2){ref-type="fig"}A). Under these conditions, T cells become unresponsive to viral antigens and persist in a non-functional, exhausted state (T~EX~), in which they are unable to clear virus effectively ([@B126]).

![**Biological and clinical implications of PD-1 ligation on T cell immune function**. **(A)** Engagement of PD-1 by PD-L1 expressed on pathogen-presenting cells inhibits differentiation, activation, and expansion of pathogen-specific T cells in chronic infections. Therapeutic blockade of this pathway can improve pathogen-specific immunity. **(B)** Engagement of PD-1 by PD-L1 expressed on tissues and APC-presenting self-antigens prevents the generation of self-reactive T effector cells, promotes the differentiation of T~Reg~ cells, suppresses expansion of escaping self-reactive T cells, and prevents autoimmunity. Therapeutic activation of this pathway may promote transplantation tolerance and induce self-tolerance in autoimmune diseases. **(C)** Engagement of PD-1 by PD-L1 expressed on cancer cells and immune cells infiltrating the tumor microenvironment (TME) inhibits expansion of tumor-specific T cells, promotes the generation of T~Reg~ cells, promotes tumor tolerance, and suppresses antitumor immunity. Therapeutic blockade of this pathway can activate antitumor immune responses.](fimmu-07-00550-g002){#F2}

During the development of exhaustion, loss of effector functions happens in a hierarchical manner: IL-2 production, high proliferative capacity and *in vitro* cytolytic activity are lost first, followed by impairment in the production of TNF-α, IFN-γ, and degranulation ([@B127], [@B128]). Although incapable of functioning as effector or memory, T~EX~ cells are not functionally dormant. Instead, they commit to the containment of chronic infections, because depleting CD8^+^ T cells including T~EX~ during simian immunodeficiency virus (SIV) infection results in rapid increase in viral titers and progression to AIDS ([@B129], [@B130]), suggesting an important role for the residual function of SIV-specific T~EX~ in maintaining a host--pathogen equilibrium and contributing to the containment of the chronic infection. T~EX~ cells often retain the capacity to produce low levels of IFN-γ and/or beta chemokines and express high levels of granzyme B. In addition, one subset of T~EX~ retains some residual cytotoxicity ([@B127], [@B131], [@B132]). High granzyme B expression is an interesting feature of T~EX~, given that the *ex vivo* killing capacity of these cells is impaired compared with T~EFF~ ([@B131], [@B132]). Thus, while T~EX~ cells exhibit impaired effector functions, some residual functionality remains, and this may be important in a host--pathogen equilibrium. In addition to PD-1, T~EX~ cells expressed higher levels of other inhibitory receptors (e.g., Tim-3, Lag-3, and CD160) as well ([@B131]). However, blockade of PD-1 is sufficient to induce reinvigoration of a significant fraction of this cell population, which selectively expresses T-bet^Hi^ Eomes^Lo^ PD-1^int^ and has the ability to proliferate after PD-1 blockade. In contrast, T~EX~ cells exhibiting Eomes^Hi^ PD-1^Hi^ are unable to respond after PD-1 blockade ([@B132]). Similar subsets of T~EX~ defined by reciprocal patterns of T-bet, Eomes, and/or PD-1 expression have been found in human patients with HCV and HIV infection ([@B133], [@B134]). In these patient populations, PD-1 blockade resulted in augmentation of pathogen-specific T cells and decrease of viral load ([@B46], [@B47]).

Role of PD-1 in Transplantation and Autoimmunity {#S7-2}
------------------------------------------------

PD-L1 is expressed on a wide variety of non-hematopoietic cells and plays a key role for the maintenance of self-tolerance (Figure [2](#F2){ref-type="fig"}B). PD-1 and PD-L1 levels increase after heart allotransplantation and their levels correlate with the likelihood of rejection, while the use of a PD-L1-Ig fusion protein decreased rejection ([@B135]). This finding was of great interest as PD-L1 is expressed in endothelial cells, which are located between the graft cells and the immune cells and suggests a potential target to decrease the rates of graft rejection. Similarly, GvHD occurring after bone marrow transplantation (BMT) has been associated with expression of PD-1 in the infiltrating cells. However, deficiency of the PD-1 pathway has also been related to higher mortality resulting from GvHD ([@B136], [@B137]).

Programed cell death 1 appears to be of major clinical relevance in autoimmune diseases, such as diabetes mellitus type I (DM I) and systemic lupus erythematosus (SLE). PD-L1 is expressed in pancreatic beta islet cells and limits the activation and harmful cytotoxic function of self-reactive T-cells against islet cells, thereby protecting from autoimune damage. Treatment of non-obese mice with PD-1- and PD-L1-blocking antibodies caused faster development of DM I, while treatment with PD-L2 blocking antibody had no effect ([@B138], [@B139]). In SLE, data that associates polymorphisms of the PD-1 gene with susceptibility to the disease in humans ([@B140]) are in line with evidence that mice deficient in PD-1 develop manifestations that resemble SLE, including glomerulonephritis and arthritis ([@B7]). Involvement of the PD-1 pathway in other autoimmune diseases, namely multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease, is also suggested by studies in animals and attributed to either absence or non-functionality of regulatory T-cells ([@B115]).

Role of PD-1 in Antitumor Immunity {#S7-3}
----------------------------------

The expression of PD-L1 and PD-L2 on APC after exposure to IFN-γ and the expression of PD-L1 in cancer cell lines ([@B15]) and primary cancer cells ([@B141]) led to the hypothesis that blockade of the PD-1:PD-L1/2 inhibitory pathway might induce antitumor immunity. The hypothesis that engagement of PD-1:PD-L1 pathway might dampen immune responses for tumors was confirmed by the observation that overexpression of PD-L1 on a mouse mastocytoma cell line inhibits CD8^+^ T cell cytolytic activity through PD-1 ligation, which intensifies tumor growth and invasiveness ([@B142]). Studies in various types of human cancers have confirmed that tumors exploit PD-1-mediated immune suppression to escape immune surveillance. A wide variety of solid tumors, including urothelial, ovarian, breast, cervical, colon, pancreatic, gastric, melanoma, glioblastoma, non-small cell lung cancer (NSCLC), and hematologic malignancies have been found to express PD-L1 and to a lesser extent PD-L2, which correlate with adverse prognosis ([@B143]--[@B149]). Importantly, the presence of PD-L1 within the tumor microenvironment (TME) also correlates with a better clinical response to PD-1/PD-L1 checkpoint blockade therapy ([@B17], [@B18], [@B150]). In addition to cancer cells, PD-L1 and PD-L2 are also expressed in other cellular components of the TME including macrophages (mostly M2), myeloid DCs, myeloid suppressor cells (MDSC), stromal fibroblasts, and endothelial cells (Figure [2](#F2){ref-type="fig"}C). Similarly to cancer cell-specific expression, PD-L1 expression on tumor-infiltrating immune cells correlates with clinical responses to PD-1:PD-L1 blockade therapy. Conversely, lack of PD-L1 upregulation in tumor cells or tumor-infiltrating immune cells correlates with lack of therapeutic response and disease progression ([@B151]).

PD-L1 expression on cancer cells can be mediated by cell intrinsic mechanisms activated by oncogenic mutations ([@B152]). PD-L1 expression on cancer cells and tumor-infiltrating immune cells can also be induced by local inflammation, i.e., type I/II IFN-gamma released by activated T cells, a condition termed "adaptive immune resistance" (Figure [2](#F2){ref-type="fig"}C) ([@B153]). It should be noted that reported studies use a different cutoff of PD-L1 expression level to define positivity and variable approaches regarding evaluation of PD-L1 expression only on cancer cells or also on tumor-infiltrating immune cells ([@B17], [@B18], [@B150]). Use of different antibodies for histopathological assessment of PD-L1 expression may also lead to variable conclusions. Regardless of these confounding factors, there is an unequivocal conclusion that the degree of PD-L1 expression in the TME positively correlates with clinical response.

When the PD-1/PD-L1 pathway is active in the TME, it promotes survival of cancer cells *via* antiapoptotic signals mediated *via* PD-L1 ([@B141], [@B154]) and inhibits the activation of signaling pathways, which are critical for survival, expansion, and differentiation of T cells that recognize tumor antigens. The imbalanced activation of signaling events in T cells results in tumor tolerance by inhibiting T effector and memory cell generation and promoting the differentiation of T~EX~ and T~Reg~ cells (Figure [3](#F3){ref-type="fig"}, left side). Importantly, high expression level of PD-1 has been detected on tumor-infiltrating T cells, compared with T cells in normal tissues and peripheral blood from the same patients and healthy donors, and correlate with an exhausted phenotype and an impaired effector function ([@B155]). Blocking the PD-1/PD-L1 pathway by anti-PD-1 or anti-PD-L1 antibodies suppresses cancer cell survival, reverses the effects of PD-1 on T cell signaling, and promotes the generation of T effector and memory cells while preventing the differentiation of T~EX~ and T~Reg~ cells. Together, these cell signaling and functional programs enhance antitumor T cell responses, leading to tumor regression and rejection (Figure [3](#F3){ref-type="fig"}, right side). It remains to be deciphered whether the therapeutic outcome of PD-1 blockade is different between patients with oncogenic PD-L1 expression versus immunogenic PD-L1 expression, in which PD-L1 is expressed on cancer cells and immune cells, respectively.

![**PD-1/PD-L1 blockade enhances tumor rejection by activating T cells**. (Left) When PD-1/PD-L1 pathway is active, promotes survival of cancer cells *via* antiapoptotic signals mediated *via* PD-L1 and inhibits signaling pathways that lead to activation and expansion of T cells that recognize tumor antigens. Together, these events lead to impaired generation of T effector and memory cells and preferentiation differentiation of T~EX~ and T~Reg~ cells, which promote tumor tolerance. (Right) Blocking the PD-1/PD-L1 immune checkpoint pathway by anti-PD-1 or anti-PD-L1 antibodies suppresses cancer cell survival and enhances the antitumor responses of T cells, leading to tumor regression and rejection. In contrast to impaired TCR signaling induced by PD-1 engagement, PD-1/PD-L1 blockade causes activation of T cells by increasing PI3K/Akt or Ras/MAPK pathways, promoting differentiation of effector and memory T cells and suppression of T~EX~ and T~Reg~ differentiation.](fimmu-07-00550-g003){#F3}

Taking the Benchwork to Clinic {#S8}
==============================

Targeted therapy against PD-1/PD-L1 has shown significant clinical activity in a variety of cancers including solid tumors and hematologic malignancies such as melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma, gastric cancer, hepatocellular carcinoma, ovarian cancer, cervical cancer, uterine cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, Merkel cell carcinoma, Hodgkin's lymphoma (HL), diffuse large B cell lymphoma, and follicular lymphoma ([@B16]--[@B19], [@B145], [@B150], [@B156]--[@B174]).

PD-1 Blockade in Melanoma {#S8-1}
-------------------------

The use of antibodies that block immune checkpoints in the treatment of solid tumors was officially established in the armory of anticancer therapies in 2010 when ipilimumab, a CTLA-4 inhibitor, showed to improve survival in metastatic melanoma and led to the FDA approval of ipilimumab for the treatment of melanoma ([@B175]). Based on the fact that -- similar to CTLA-4 -- PD-1 is a coinhibitory receptor, antibodies have been developed with the goal to inhibit the PD-1:PD-L1 pathway (Table [1](#T1){ref-type="table"}). These antibodies have generated remarkable responses in a wide spectrum of cancers (Table [2](#T2){ref-type="table"}) and have shown better clinical benefit and better toxicity profile than CTLA4-blocking antibodies ([@B158], [@B170]).

###### 

**Inhibitory antibodies of the PD1:PD-L1 pathway in clinical development**.

  Checkpoint target           Blocking agent           Type of antibody                      Developmental stage                         Source
  --------------------------- ------------------------ ------------------------------------- ------------------------------------------- ----------------------
  PD-1                        Nivolumab (BMS-936558)   Human Ig4                             FDA approved for melanoma, NSCLC, and RCC   Bristol-Myers Squibb
  Pembrolizumab (MK-3475)     Humanized IgG4           FDA approved for melanoma and NSCLC   Merck                                       
  MEDI0680 (AMP-514)          Humanized IgG4           Phase I                               Medimmune                                   
  PD-L1                       Durvalumab (MEDI4736)    Human IgG4                            Phase III                                   Medimmune
  Atezolizumab (MPDL-3280A)   Human IgG1               Phase III                             Genentech                                   
  MDX-1105/BMS-936559         Human IgG4               Phase I                               Bristol-Myers Squibb                        
  Avelumab (MSB0010718C)      Human IgG1               Phase II                              Merck Serono                                

###### 

**Examples of clinical trials with antibodies blocking the PD-1:PD-L1 pathway**.

  Cancer types                                                 Blocking agents                                                                                                                                                                                    Clinical response rate
  ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Melanoma                                                     Nivolumab                                                                                                                                                                                          12.8% in treatment-refractory metastatic melanoma, 28% in advanced melanoma, 40% in melanoma treated in combination with ipilimumab, 20% in nivolumab followed by iplimumab, 40% in previously untreated melanoma without BRAF mutation, 57.6% (nivolumab plus iplimumab) versus 19% (ipilimumab) versus 43.7% (nivolumab) in untreated stage III or IV melanoma
  Pembrolizumab                                                38% in comparison to chemotherapy (14%), 26% in ipilimumab-refractory advanced melanoma, 33% in comparison to ipilimumab (11.9%) in advanced melanoma                                              
  Atezolizumab                                                 21% objective response rate                                                                                                                                                                        
  MDX-1105                                                     17.3% objective response rate                                                                                                                                                                      
                                                                                                                                                                                                                                                                  
  NSCLC                                                        Nivolumab                                                                                                                                                                                          12.8% in treatment-refractory metastatic NSCLC, 18% in advanced NSCLC, 14.5% in refractory NSCLC, 17% in previously treated NSCLC, 20% in advanced squamous cell NSCLC, higher overall survival (12.2 months) versus docetaxel treatment (6 months)
  Pembrolizumab                                                63 versus 0% in stage IV NSCLC patients with high and low non-synonymous mutation burden, 19.4% in advanced NSCLC of unselected population, 45.2% objective response rate in PD-L1^+^ population   
  Durvalumab                                                   14% objective response rate in unselected population and 23% in PD-L1^+^ population                                                                                                                
  Atezolizumab                                                 15% objective response rate in unselected population and 38% in PD-L1^+^ population                                                                                                                
  MDX-1105                                                     10.2% in NSCLC                                                                                                                                                                                     
                                                                                                                                                                                                                                                                  
  Renal cell carcinoma                                         Nivolumab                                                                                                                                                                                          Higher overall survival (25 months) and better objective response rate (25%) in comparison to everolimus treatment (19.6 months and 5% ORR)
  Atezolizumab                                                 21% overall response rate                                                                                                                                                                          
  MDX-1105                                                     11.7% response rate                                                                                                                                                                                
                                                                                                                                                                                                                                                                  
  Breast cancer                                                Atezolizumab                                                                                                                                                                                       19% objective response rate
  Pembrolizumab                                                18.5% response rate                                                                                                                                                                                
                                                                                                                                                                                                                                                                  
  Small cell lung cancer                                       Nivolumab                                                                                                                                                                                          18% objective response rate in monotherapy and 17% objective response rate in combination
  Pembrolizumab                                                35% response rate                                                                                                                                                                                  
  Atezolizumab                                                 21% objective response rate                                                                                                                                                                        
                                                                                                                                                                                                                                                                  
  Head and neck                                                Durvalumab                                                                                                                                                                                         12% objective response rate
  Pembrolizumab                                                24.8% objective response rate observed in both HPV^+^ and HPV^−^ patients                                                                                                                          
  Atezolimumb                                                  19% objective response rate                                                                                                                                                                        
                                                                                                                                                                                                                                                                  
  Hepatocellular carcinoma                                     Nivolumab                                                                                                                                                                                          19% objective response rate
                                                                                                                                                                                                                                                                  
  Gastric cancer                                               Nivolumab                                                                                                                                                                                          31% response rate
  Atezolizumab                                                 21% overall response rate                                                                                                                                                                          
                                                                                                                                                                                                                                                                  
  Ovarian cancer                                               Nivolumab                                                                                                                                                                                          15% response rate, responses lasted up to 17 months
  Avelumab                                                     14.7% objective response rate                                                                                                                                                                      
  Pembrolizumab                                                11.5% response rate                                                                                                                                                                                
  Atezolizumab                                                 21% overall response rate                                                                                                                                                                          
  MDX-1105                                                     5.9% response rate                                                                                                                                                                                 
                                                                                                                                                                                                                                                                  
  Bladder cancer                                               Atezolizumab                                                                                                                                                                                       26% objective response rate in unselected population and 43% in PD-L1^+^ population
  Pembrolizumab                                                25% objective response rate in unselected population and 38% in PD-L1^+^ population                                                                                                                
                                                                                                                                                                                                                                                                  
  Mismatch repair-deficient carcinoma (colorectal and other)   Pembrolizumab                                                                                                                                                                                      40% objective response rate in repair-deficient CRC, 0% in repair-sufficient CRC, 71% in mismatch repair-deficient non-colorectal carcinomas
                                                                                                                                                                                                                                                                  
  Merkel cell carcinoma                                        Pembrolizumab                                                                                                                                                                                      71% objective response rate
                                                                                                                                                                                                                                                                  
  Hodgkin's lymphoma                                           Nivolumab                                                                                                                                                                                          87% objective response in relapsed or refractory Hodgkin's lymphoma
  Pembrolizumab                                                66% overall response rate                                                                                                                                                                          

Nivolumab, an IgG4 PD-1 antibody, binds to PD-1 with high affinity and specificity and was the first PD-1 blocking agent to demonstrate clinical activity in several different types of cancers, including melanoma, RCC, and NSCLC in a phase I/II trial completed in 2012 ([@B18]). In a phase Ib dose escalation study, 32% of the patients with advanced melanoma developed durable remission, which correlated with expression of PD-L1 in the tumor cells defined as positive at a minimum level of 5% ([@B18], [@B168]). Subsequently, in a phase III study, which compared nivolumab with dacarbazine in patients with melanoma without B-Raf mutation, nivolumab was associated with a survival benefit (73 versus 42%) and higher objective response rate (40 versus 14%). The response rate of patients with PD-L1-positive tumors (defined as PD-L1-positive tumor cells \>5%) was also better than in patients with PD-L1-negative/intermediate tumors (53 versus 33%) ([@B150]). In the second phase III trial, nivolumab was compared with chemotherapy in patients with advanced melanoma non-responsive to ipilimumab (or ipililumab and BRAF inhibitor in BRAF-mutant tumors). A response rate of 32% was noted in the nivolumab treatment group versus 11% in the chemotherapy treatment group. This study also found PD-L1 as a response-predictive biomarker with 44% response rate in PD-L1 positive versus 20% in the PD-L1 negative tumors ([@B171]). Based on these outcomes, FDA approved nivolumab on December 22, 2014 for the treatment of patients with melanoma, whose disease state has progressed after prior treatment.

Pembrolizumab is a very high affinity humanized IgG4 antibody directed against human PD-1. Randomized trials have been performed in both ipilimumab naïve (NCT01866319) and previously treated patients (NCT01704287). Promising results in preliminary studies ([@B165], [@B166]) led to a phase II dose escalation trial comparing two dose levels of pembrolizumab to chemotherapy in ipilimumab-refractory melanoma patients ([@B176]). This study showed clear benefit for both groups that received pembrolizumab with 6-month progression-free survival (PFS) of 34 and 38% compared to the PFS of 16% of the chemotherapy group. A subsequent phase III trial compared the treatment outcome of two different administration schedules of pembrolizumab to ipilimumab in patients with advanced melanoma and provided evidence of improved survival rate in both pembrolizumab treatment groups compared to the ipilimumab group (74 and 68 versus 58%) ([@B158]). On September 4, 2014 pembrolizumab was approved by FDA for the treatment of advanced melanoma in patients previously treated with ipilimumab or a BRAF inhibitor in BRAF V600 mutation positive patients. To date, both nivolumab and pembrolizumab have also been approved by FDA and used for treatment in NSCLC, head and neck cancer, RCC, and Hodgkin lymphoma.

PD-1 Blockade in NSCLC {#S8-2}
----------------------

The success of PD-1 blocking antibodies in NSCLC has made headlines since checkpoint blockade was thought to be responsive solely in immunogenic tumors like melanoma and RCC. A phase I dose-evaluating study of nivolumab has shown responses in patients with squamous and non-squamous histology, with or without EGFR or KRAS mutations, with or without tumor PD-L1 expression, and across different dose levels ([@B18]). On the basis of these preliminary results, two randomized phase III studies were undertaken. One compared nivolumab to docetaxel in advanced squamous NSCLC and found an improved median overall survival (OS) (9.2 versus 6.0 months) ([@B172]). In this study, tumor expression of PD-L1 determined at three different expression cutoff levels (1, 5, and 10%) had neither prognostic nor predictive of treatment benefit. The second study followed the same design and studied responses of patients with non-squamous NSCLC. In this patient group, nivolumab also resulted in improved median OS benefit compared to docetaxel (12.2 versus 9.4 months) while the OS at 1 year was 51% in the nivolumab group versus 39% in the docetaxel group ([@B177]). Correlations between therapeutic benefit and PD-L1 expression on tumor cells at the same cutoff levels (1, 5, and 10%) was also studied. In contrast to the observations in patients with advanced squamous NSCLC ([@B172]), patients with PD-L1-positive non-squamous NSCLC tumors had therapeutic benefit over those with PD-L1-negative tumors and this was observed across all three PD-L1 expression levels. Nivolumab was approved by FDA in March, 2015 for treatment of squamous NSCLC, and eventually for all patients with advanced NSCLC progressing after platinum-based chemotherapy on October 9, 2015. Almost in parallel, FDA also approved Pembrolizumab on October 2, 2015 for PD-L1-positive NSCLC, based on a large clinical trial, which assessed efficacy and safety of pembrolizumab in patients with advanced NSCLC ([@B17]). As in previous studies, therapeutic benefit was correlated with tumor PD-L1 positivity, which in this study was defined at the \>50% cutoff. Importantly, this study also provided evidence that a striking survival benefit was observed in patients who received pembrolizumab without prior treatment with chemotherapy.

PD1:PD-L1 Blockade in Other Cancers {#S8-3}
-----------------------------------

More than 100 trials are currently investigating the use of PD-1 blockade agents as monotherapy or in combination with chemotherapeutic agents, targeted therapies, or alternate immunotherapy modalities for multiple tumor types (<http://clinicaltrials.gov>).

For RCC, immunotherapy has always been considered as a primary therapeutic strategy because of its immunogenic nature. The rationale for treatment with PD-1:PD-L1 blockade in RCC was further supported by the excessive PD-L1 expression in inflamed and cancerous kidney tissues ([@B178]). A randomized phase II trial comparing different doses of nivolumab in advanced RCC patients has shown a long-lasting objective response in about 22% of the patients ([@B179]). Currently, a combinatorial treatment regimen of nivolumab with either sunitinib or pazopanib is being developed, which has shown better efficacy, but higher toxicity ([@B180]). The efficacy of pembrolizumab is also currently being evaluated in a phase I/II trial in treatment naïve metastatic RCC patients in combination with pazopanib or axitinib.

One of the most impressive responses has been observed in HL, in which PD-1 blockade with nivolumab resulted in response rate of 87% ([@B19], [@B181], [@B182]). This outcome is based on the molecular upregulation of the PD-1:PD-L1 pathway through amplification of 9p24.1, which increases the gene dosage of PD-L1 and PD-L2 together with Jak2 in nodular sclerosing HL ([@B183]).

Currently, ongoing clinical trials are investigating PD-L1 blocking antibodies. Such antibodies, specifically MPDL3280A (Atezolizumab) and MEDI4736 (Durvalumab) are being evaluated in metastatic melanoma. Interestingly, Atezolizumab was associated with good responses and less pulmonary toxicity compared to PD-1 antibodies ([@B184]). In a randomized phase II trial, Atezolizumab is being compared with platinum-based chemotherapy and docetaxel after platinum failure in NSCLC. Durvalumab in combination with an EGFR inhibitor is being compared to chemoradiation in stage III NSCLC, where an objective response rate of 14% has been noticed across all histologies ([@B185], [@B186]). Atezolizumab is also currently being investigated as monotherapy or in combination with bevacizumab in comparison to a control group of sunitinib in treatment-naïve locally advanced or metastatic RCC. In a recent study, one complete and two partial responses were observed in patients with recurrent or metastatic triple negative breast cancer who are PD-L1 positive. PD-L1 blockade therapy also appears to be effective in bladder cancer. In a phase I study of atezolizumab in advanced bladder cancer, an objective response rate of 43% has been observed in tumors expressing high levels of PD-L1 ([@B160]).

Combination Approaches {#S8-4}
----------------------

The combination of checkpoint blockade was first tested in advanced melanoma patients treated with nivolumab and ipilimumab and the resulting clinical activity was phenomenal ([@B187]). In a phase II study, the objective response rate for nivolumab plus ipilimumab was 59% in comparison to 11% with ipilimumab alone ([@B188]). Most recently, a phase III study of nivolumab plus ipilimumab versus nivolumab versus ipilimumab was performed in treatment naïve advanced melanoma patients ([@B170]). Again, the response rate was 57.6% for the combination therapy in comparison to 43.7% for nivolumab and 19% for ipilimumab monotherapies. The improved outcomes of the combination therapy over ipilimumab alone appear to be sustained within the 2-year follow-up of patients with combination therapy ([@B189]). The combination approach was also tested in patients with metastatic RCC. In this patient group, ipilimumab plus nivolumab in two different dose levels gave a response rate of 43 and 48%, respectively ([@B190]). Comparison between the combination checkpoint immunotherapy and sunitinib in advanced RCC is under investigation.

In NSCLC, a phase III study of nivolumab plus ipilimumab versus nivolumab monotherapy versus chemotherapy is currently undergoing (NCT02477826). Promising results were also reported from a phase I study of combination of Durvalumab and tremelimumab in NSCLC. Also, another phase III study in untreated, advanced NSCLC has recently begun with durvalumab plus tremelimumab versus durvalumab versus chemotherapy (NCT02453282). The combinatorial studies examining efficacy and safety of these drugs are also been undertaken in several other malignancies, including SCLC ([@B191]), gastric, and bladder cancer (NCT01928394). Because of different cellular expression/localization of PD-1 and PD-L1 in normal tissues, the tolerability of combination of PD-1 plus PD-L1 is also being investigated (NCT02118337).

Determinants of Response {#S8-5}
------------------------

In order to understand how PD-1 blockade imparts tumor rejection, it is critical to identify the cell population(s) that are targeted and altered during antibody treatment ([@B192]). The presence of PD-L1 within TME in more than 1% of tumor cells has been shown to correlate with a better clinical response to PD-1/PD-L1 checkpoint blockade therapy. In contrast, lack of PD-L1 upregulation in tumor cells or lack of tumor-infiltrating immune cells has been observed in most progressing patients ([@B18], [@B151], [@B193]). However, studies in RCC have determined that detectable tumor expression of PD-L1 can be documented only in a small fraction of patients (20--30%), yet, a higher number of patients with PD-L1 negative RCC responded to PD-1 blockade ([@B194]).

As mentioned above, in addition to tumors, PD-L1 expression on tumor-infiltrating immune cells, mainly myeloid APC (macrophage and myeloid DCs) correlates with clinical responses to PD-1:PD-L1 blockade therapy ([@B151]). Based on these findings, it is possible that therapeutic PD-1 blockade might work more effectively if the tumors have already been identified by the host immune system and PD-L1 expression in cancer and innate immune cells is the consequence of local IFN-γ production by tumor-activated T cells ([@B151], [@B193]). Thus, one key approach to understand which cell types are important for tumor rejection is to determine location, density, and phenotype of the immune cells inside the TME and their spatiotemporal expression of PD-1 and PD-L1. Techniques to achieve this goal include, but not limited to, slide-based quantitative immunehistochemistry (IHC) and quantitative multiplexed IHC *in situ* gene expression assay ([@B193], [@B195]--[@B197]). The use of different anti PD-1 and anti PD-L1 antibodies, the different cutoff points to measure expression, the different cell types in which expression is being evaluated and the different scoring systems used by various pathology laboratories has caused difficulty in harmonizing the IHC readouts. The Cancer Immunotherapy Trials Network has started to review the immunodynamic effects of checkpoint inhibitors with the goal to identify and define immune assessment modalities and sites, both systemic and intratumoral, which are critical to the therapeutic success ([@B198]). Refining immune endpoints will provide the tools for the design of improved clinical trials, for selection of appropriate candidate patients for PD-1-based immunotherapy, and for assessment of induction and maintenance of therapeutic response.

Conclusion and Future Directions {#S9}
================================

Programed cell death 1 is involved in the induction and maintenance of peripheral tolerance and plays a crucial role in the regulation of autoimmunity, transplantation immunity, infectious immunity, and tumor immunity. Currently, in parallel with the development of new discoveries about the molecular mechanisms of PD-1 function, clinical trials of combinatorial approaches are emerging. Such studies aim to maximize therapeutic antitumor benefit by blocking PD-1 together with other checkpoint inhibitors -- such as CTLA-4, LAG3, TIM3, or by blocking PD-1 while engaging activating receptors of the TNF superfamily with agonist antibodies. Furthermore, PD-1 blockade together with chemoradiotherapy is anticipated to extend the therapeutic benefits of PD-1 checkpoint inhibition to a higher number of patients.
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